Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
Novo Nordisk is facing its worst week this year — after that Hims & Hers Super Bowl ad
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...
pharmaphorum23h
Novo Nordisk grabs NASH drug from Ventus in $703m deal
Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...